Diversified Enterprises LLC Sells 887 Shares of CVS Health Corporation $CVS

Diversified Enterprises LLC cut its stake in CVS Health Corporation (NYSE:CVS) by 20.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,548 shares of the pharmacy operator’s stock after selling 887 shares during the period. Diversified Enterprises LLC’s holdings in CVS Health were worth $245,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CVS. Vanguard Group Inc. grew its position in CVS Health by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 118,335,394 shares of the pharmacy operator’s stock worth $8,017,223,000 after purchasing an additional 969,027 shares in the last quarter. Dodge & Cox grew its position in shares of CVS Health by 4.8% during the first quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock valued at $4,976,856,000 after purchasing an additional 3,353,223 shares in the last quarter. Invesco Ltd. grew its holdings in CVS Health by 13.2% during the 1st quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock worth $1,383,039,000 after acquiring an additional 2,375,764 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in CVS Health by 14.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,309,289 shares of the pharmacy operator’s stock valued at $1,037,205,000 after purchasing an additional 1,942,886 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of CVS Health by 5.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 13,647,873 shares of the pharmacy operator’s stock worth $924,643,000 after purchasing an additional 728,924 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Price Performance

NYSE CVS opened at $75.80 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.80 and a quick ratio of 0.62. The firm has a market capitalization of $96.14 billion, a PE ratio of 21.17, a P/E/G ratio of 0.84 and a beta of 0.62. CVS Health Corporation has a 12 month low of $43.56 and a 12 month high of $77.34. The company’s 50 day simple moving average is $69.13 and its 200 day simple moving average is $66.99.

CVS Health (NYSE:CVS) last announced its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, topping the consensus estimate of $1.46 by $0.35. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The firm had revenue of $98.92 billion for the quarter, compared to the consensus estimate of $94.87 billion. During the same quarter last year, the firm posted $1.83 EPS. The business’s quarterly revenue was up 8.4% on a year-over-year basis. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts forecast that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd will be issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date of this dividend is Thursday, October 23rd. CVS Health’s dividend payout ratio is presently 74.30%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on CVS shares. Barclays boosted their price target on shares of CVS Health from $80.00 to $87.00 and gave the stock an “overweight” rating in a research report on Thursday, September 4th. Baird R W raised CVS Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Robert W. Baird upgraded shares of CVS Health from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $71.00 to $82.00 in a research report on Thursday, August 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $78.00 target price on shares of CVS Health in a research report on Tuesday, August 26th. Finally, UBS Group raised CVS Health from a “neutral” rating to a “buy” rating and raised their target price for the stock from $67.00 to $79.00 in a research note on Monday, August 18th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $78.25.

Insider Activity at CVS Health

In other news, Director Anne A. Finucane sold 7,500 shares of the business’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total transaction of $532,650.00. Following the sale, the director owned 22,156 shares in the company, valued at approximately $1,573,519.12. The trade was a 25.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.22% of the company’s stock.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.